ZA95692B - Neuroprotective compounds - Google Patents

Neuroprotective compounds

Info

Publication number
ZA95692B
ZA95692B ZA95692A ZA95692A ZA95692B ZA 95692 B ZA95692 B ZA 95692B ZA 95692 A ZA95692 A ZA 95692A ZA 95692 A ZA95692 A ZA 95692A ZA 95692 B ZA95692 B ZA 95692B
Authority
ZA
South Africa
Prior art keywords
pct
sec
date
neuroprotective compounds
pub
Prior art date
Application number
ZA95692A
Other languages
English (en)
Inventor
Todd W Butler
Bertrand L Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA95692B publication Critical patent/ZA95692B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA95692A 1994-01-31 1995-01-30 Neuroprotective compounds ZA95692B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
ZA95692B true ZA95692B (en) 1996-07-30

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95692A ZA95692B (en) 1994-01-31 1995-01-30 Neuroprotective compounds

Country Status (27)

Country Link
US (1) US5744483A (fr)
EP (1) EP0741724B1 (fr)
JP (1) JP2866743B2 (fr)
CN (1) CN1048247C (fr)
AT (1) ATE183184T1 (fr)
AU (1) AU684568B2 (fr)
BR (2) BR9408506A (fr)
CA (1) CA2182101C (fr)
CO (1) CO4230161A1 (fr)
CZ (1) CZ286757B6 (fr)
DE (1) DE69420053T2 (fr)
DK (1) DK0741724T3 (fr)
EG (1) EG20672A (fr)
ES (1) ES2134361T3 (fr)
FI (1) FI113769B (fr)
GR (1) GR3031356T3 (fr)
HU (1) HU221633B1 (fr)
IL (1) IL112415A (fr)
MY (1) MY111623A (fr)
NO (1) NO309190B1 (fr)
NZ (1) NZ275151A (fr)
PE (1) PE43795A1 (fr)
PL (1) PL179448B1 (fr)
RU (1) RU2126404C1 (fr)
TW (1) TW449591B (fr)
WO (1) WO1995020587A1 (fr)
ZA (1) ZA95692B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509839A (ja) * 1995-09-15 1999-08-31 ファイザー・インコーポレーテッド 薬剤活性を有するフェノール誘導体
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
US6407235B1 (en) * 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1674087A1 (fr) 2000-10-02 2006-06-28 Pfizer Products Inc. Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
BR0211358A (pt) * 2001-07-26 2004-09-21 Merck Patent Gmbh Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
RU2240113C1 (ru) * 2003-01-23 2004-11-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова Способ экстренной медикаментозной помощи при острой травме спинного мозга
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
WO2007051735A1 (fr) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Dérivés d'indolylmaléimide en tant qu'inhibiteurs de protéine kinase
MX2008009414A (es) * 2006-01-20 2008-10-01 Schering Corp Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa.
RU2418578C1 (ru) * 2009-12-08 2011-05-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА
EP2522647B1 (fr) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Procédé de séparation d'isomères chiraux de composés de chromane et leurs dérivés et précurseurs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (fr) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (fr) * 1978-07-03 1980-02-07 Sandoz Ag Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
EP0093534A1 (fr) * 1982-04-28 1983-11-09 Beecham Group Plc Chromanols
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2546166B1 (fr) * 1983-05-19 1985-10-25 Synthelabo Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1990014087A1 (fr) * 1989-05-17 1990-11-29 Pfizer Inc. Derives de 2-piperidino-1-alcanol en tant qu'agents antiischemiques
RU2099339C1 (ru) * 1990-02-06 1997-12-20 Пфайзер Инк. Производные пиперидина
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
HU9602100D0 (en) 1996-09-30
NZ275151A (en) 1998-02-26
US5744483A (en) 1998-04-28
FI950403A0 (fi) 1995-01-30
IL112415A0 (en) 1995-03-30
DE69420053D1 (de) 1999-09-16
FI113769B (fi) 2004-06-15
RU2126404C1 (ru) 1999-02-20
CN1048247C (zh) 2000-01-12
CZ286757B6 (en) 2000-06-14
CA2182101A1 (fr) 1995-08-03
NO963186D0 (no) 1996-07-30
DK0741724T3 (da) 1999-12-20
ATE183184T1 (de) 1999-08-15
JP2866743B2 (ja) 1999-03-08
ES2134361T3 (es) 1999-10-01
PE43795A1 (es) 1995-12-09
CO4230161A1 (es) 1995-10-19
AU8066394A (en) 1995-08-15
MY111623A (en) 2000-09-27
EG20672A (en) 1999-11-30
EP0741724A1 (fr) 1996-11-13
EP0741724B1 (fr) 1999-08-11
CN1142825A (zh) 1997-02-12
IL112415A (en) 1999-07-14
AU684568B2 (en) 1997-12-18
NO963186L (no) 1996-07-30
HU221633B1 (hu) 2002-12-28
CZ225696A3 (en) 1997-01-15
CA2182101C (fr) 1999-08-03
DE69420053T2 (de) 1999-11-25
GR3031356T3 (en) 2000-01-31
PL179448B1 (pl) 2000-09-29
TW449591B (en) 2001-08-11
HUT75942A (en) 1997-05-28
PL315681A1 (en) 1996-11-25
FI950403L (fi) 1995-08-01
WO1995020587A1 (fr) 1995-08-03
JPH09501698A (ja) 1997-02-18
NO309190B1 (no) 2000-12-27
BR9500380A (pt) 1995-10-17
BR9408506A (pt) 1997-08-05

Similar Documents

Publication Publication Date Title
EG20672A (en) Neuroprotective compounds
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
IL114683A0 (en) Combination treatment for inhibiting bone loss
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
GB9104890D0 (en) Compositions
IL127044A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenertive diseases
IL112288A0 (en) Application of riluzole in the treatment of mitochondrial diseases
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
EP0653936A1 (fr) Utilisation de la 2-(4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinone dans le traitement du cancer.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
BG105289A (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders